Health Technology Assessment Agencies
Agencies evaluating the cost-effectiveness and clinical value of psychedelic therapies for healthcare system coverage decisions.
All Organisations
Canadian Drug Agency (CDA-AMC)
Canadian public HTA and reimbursement review body supporting evidence appraisal for access decisions.
Federal Joint Committee (G-BA)
Germany’s highest joint self-governing HTA decision body for coverage and evidence appraisal, including esketamine/Spravato dossiers.
National Centre for Pharmacoeconomics (NCPE)
Ireland’s national HTA and pharmacoeconomics body that conducts rapid review and full HTA for reimbursement decisions, including esketamine references.
National Institute for Health and Care Excellence (NICE)
UK HTA body issuing evidence and cost-effectiveness recommendations that influence medicine access.
Oregon Health Authority Pharmacy & Therapeutics Committee
State-level Oregon pharmacy and therapeutics decision body supporting evidence-driven formulary and utilization policy.
Pharmaceutical Benefits Advisory Committee (PBAC)
Australia’s HTA and reimbursement advisory body for PBS listing decisions, including esketamine (Spravato) assessment materials.
Scottish Medicines Consortium (SMC)
Scotland’s public HTA body issuing medicine acceptance guidance, including esketamine (Spravato) advice.
Washington State Health Care Authority Health Technology Assessment Program
Washington State HTA program conducting evidence review that informs state coverage and utilization policy.